Show simple item record

dc.contributor.authorNtellas, P.
dc.contributor.authorKamposioras, Konstantinos
dc.contributor.authorGazouli, I.
dc.contributor.authorGermataki, T.
dc.contributor.authorDadouli, K.
dc.contributor.authorZarkavelis, G.
dc.contributor.authorAmylidi, A. L.
dc.contributor.authorMavroeidis, L.
dc.contributor.authorGkoura, S.
dc.contributor.authorTolia, M.
dc.contributor.authorMauri, D.
dc.date.accessioned2021-10-28T09:26:16Z
dc.date.available2021-10-28T09:26:16Z
dc.date.issued2021en
dc.identifier.citationNtellas P, Kamposioras K, Gazouli I, Germataki T, Dadouli K, Zarkavelis G, et al. 1408P Efficacy of immunotherapy in the first line treatment of advanced upper gastrointestinal tract malignancies: A pooled analysis of randomized clinical trials. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S1059.en
dc.identifier.doi10.1016/j.annonc.2021.08.1517en
dc.identifier.urihttp://hdl.handle.net/10541/624722
dc.description.abstractBackground Upper gastrointestinal tract malignancies include cancers of the oesophagus, gastro-esophageal junction and stomach. For the management of advanced disease, chemotherapy remains the primary treatment option in the 1st line, but the use of immune checkpoint inhibitors is a rapidly evolving field of research. Methods The volume of data from randomized clinical trials of the use of immunotherapy in upper gastrointestinal malignancies is steadily increasing over the last five years. Thus, we performed a systematic literature search and a pooled analysis of the available data, including both published articles and conference abstracts to identify trials evaluating immune checkpoint inhibitors in the 1st line of upper gastrointestinal malignancies. Results We identified overall four randomized trials comparing the addition of immunotherapy vs. standard chemotherapy as 1st line regimen in upper gastrointestinal malignancies. A total of 3561 patients were randomized, 1781 of whom received combination chemotherapy with immunotherapy and 1780 received standardized chemotherapy. The addition of immune checkpoint inhibitors in the first-line has been shown to benefit overall survival of patients compared to chemotherapy alone (HR = 0.81, 95% CI 0.75-0.87, p <0.00001) with a reduction in the risk of death by 20%, and up to 30% in a population of patients with CPS> 5%. Progression free survival was also increased by the addition of immunotherapy to chemotherapy (HR = 0.75, 95% CI 0.69 -0.81, p <0.00001). Furthermore, the addition of immunotherapy to chemotherapy appears to lead to a 70% increase in objective responses compared to chemotherapy alone. Conclusions The above findings pose new bases for the management of advanced upper gastrointestinal malignancies in the 1st line, highlighting the important role of immunotherapy in combination with standard chemotherapy.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2021.08.1517en
dc.titleEfficacy of immunotherapy in the first line treatment of advanced upper gastrointestinal tract malignancies: A pooled analysis of randomized clinical trialsen
dc.typeOtheren
dc.contributor.departmentMedical Oncology, University Hospital of Ioannina, Ioannina, Greeceen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2021-11-03T10:22:02Z


Files in this item

Thumbnail
Name:
AnnOncNtellas.pdf
Size:
85.90Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record